

PHARMACY POLICY STATEMENT

North Carolina Marketplace

DRUG NAME

Apretude (cabotegravir extended-release)

DATE	ACTION/DESCRIPTION
01/12/2022	New policy for Aprelude created.
05/11/2023	Simplified HIV RNA testing requirement and removed 7-day window; added quantity limit.
08/16/2023	Rephrased trial of oral PrEP to patient is not a candidate for oral PrEP and added examples.

References:

1. Aprelude [package insert]. Research Triangle Park, NC; GlaxoSmithKline. February 2023.